Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent
Chow, Diana S-L
Teng, Yang Angela
Toups, Elizabeth G
Harrop, James S
Schmitt, Karl M
Johnson, Michele M
Guest, James D
Shaffrey, Christopher I
Frankowski, Ralph F
Fehlings, Michael G
Grossman, Robert G
JournalJournal of Clinical Pharmacology
MetadataShow full item record
AbstractRiluzole, a benzothiazole sodium channel blocker that received US Food and Drug Administration approval to attenuate neurodegeneration in amyotrophic lateral sclerosis in 1995, was found to be safe and potentially efficacious in a spinal cord injury (SCI) population, as evident in a phase I clinical trial. The acute and progressive nature of traumatic SCI and the complexity of secondary injury processes can alter the pharmacokinetics of therapeutics. A 1-compartment with first-order elimination population pharmacokinetic model for riluzole incorporating time-dependent clearance and volume of distribution was developed from combined data of the phase 1 and the ongoing phase 2/3 trials. This change in therapeutic exposure may lead to a biased estimate of the exposure-response relationship when evaluating therapeutic effects. With the developed model, a rational, optimal dosing scheme can be designed with time-dependent modification that preserves the required therapeutic exposure of riluzole. © 2021 The Authors..
Rights/Terms© 2021 The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/16231
- Pharmacology of riluzole in acute spinal cord injury.
- Authors: Chow DS, Teng Y, Toups EG, Aarabi B, Harrop JS, Shaffrey CI, Johnson MM, Boakye M, Frankowski RF, Fehlings MG, Grossman RG
- Issue date: 2012 Sep
- Efficacy of riluzole in the treatment of spinal cord injury: a systematic review of the literature.
- Authors: Srinivas S, Wali AR, Pham MH
- Issue date: 2019 Mar 1
- Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial.
- Authors: Fehlings MG, Wilson JR, Frankowski RF, Toups EG, Aarabi B, Harrop JS, Shaffrey CI, Harkema SJ, Guest JD, Tator CH, Burau KD, Johnson MW, Grossman RG
- Issue date: 2012 Sep
- A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury.
- Authors: Grossman RG, Fehlings MG, Frankowski RF, Burau KD, Chow DS, Tator C, Teng A, Toups EG, Harrop JS, Aarabi B, Shaffrey CI, Johnson MM, Harkema SJ, Boakye M, Guest JD, Wilson JR
- Issue date: 2014 Feb 1
- Rationale, design and critical end points for the Riluzole in Acute Spinal Cord Injury Study (RISCIS): a randomized, double-blinded, placebo-controlled parallel multi-center trial.
- Authors: Fehlings MG, Nakashima H, Nagoshi N, Chow DS, Grossman RG, Kopjar B
- Issue date: 2016 Jan